uniQure Announces the Appointment of Rachelle Jacques to its Board of Directors
October 21, 2021 09:30 ET
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, Oct. 21, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...
uniQure Announces Presentations at the Annual Meeting of The European Society of Gene and Cell Therapy (ESGCT)
October 19, 2021 07:05 ET
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, The Netherlands, Oct. 19, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with...
uniQure to Participate in Multiple Upcoming Industry Conferences in October
September 30, 2021 07:05 ET
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, Sept. 30, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...
uniQure to Participate in Multiple Upcoming Industry Conferences in September
September 07, 2021 07:05 ET
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, Sept. 07, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...
uniQure Announces Completion of Additional Patient Procedures Following Positive Recommendation from Data Safety Monitoring Board in Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease
August 30, 2021 07:05 ET
|
uniQure Inc.
~ No Significant Safety Concerns Observed Across a Total of 14 Completed Procedures ~ ~ Full Study Enrollment Expected to be Completed by Mid-2022 ~ LEXINGTON, Mass. and AMSTERDAM, The Netherlands,...
uniQure Announces Second Quarter 2021 Financial Results and Highlights Recent Company Progress
July 26, 2021 07:05 ET
|
uniQure Inc.
~ Expanded gene therapy pipeline with four new research programs and announced acquisitionof Corlieve Therapeutics ~ ~ Presented positive 52-week data from HOPE-B pivotal study demonstrating...
uniQure Announces Presentations at Upcoming International Society on Thrombosis and Haemostasis (ISTH) Virtual Congress
July 02, 2021 09:00 ET
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, The Netherlands, July 02, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with...
uniQure Announces Positive 52-Week Clinical Data from HOPE-B Pivotal Trial of Etranacogene Dezaparvovec Gene Therapy in Patients with Hemophilia B and Provides Regulatory Update
June 22, 2021 11:31 ET
|
uniQure Inc.
~ Sustained increases in Factor IX (FIX) levels with mean FIX activity of 41.5 percent of normal in full study population one year following a single administration of etranacogene dezaparvovec ~ ~...
uniQure to Acquire Corlieve Therapeutics and Advance its Gene Therapy Program to Treat Temporal Lobe Epilepsy (TLE)
June 22, 2021 11:31 ET
|
uniQure Inc.
~ Expands uniQure’s Pipeline of Innovative Gene Therapies to Treat Neurological Disorders ~ ~ Strengthens uniQure’s Global Leadership in the Development of Gene Therapies that Employ miRNA Silencing...
uniQure Announces Enrollment of First Two Patients in Second Cohort of Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease
June 16, 2021 07:05 ET
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, The Netherlands, June 16, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with...